CHD1
Basic information
Region (hg38): 5:98853985-98929007
Links
Phenotypes
GenCC
Source:
- Pilarowski-Bjornsson syndrome (Limited), mode of inheritance: AD
- Pilarowski-Bjornsson syndrome (Supportive), mode of inheritance: AD
- Pilarowski-Bjornsson syndrome (Limited), mode of inheritance: Unknown
- complex neurodevelopmental disorder (Limited), mode of inheritance: AR
- Pilarowski-Bjornsson syndrome (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Pilarowski-Bjornsson syndrome | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Neurologic | 28866611 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (178 variants)
- not_specified (128 variants)
- Pilarowski-Bjornsson_syndrome (81 variants)
- CHD1-related_disorder (27 variants)
- EBV-positive_nodal_T-_and_NK-cell_lymphoma (2 variants)
- Complex_neurodevelopmental_disorder (2 variants)
- See_cases (2 variants)
- Neurodevelopmental_disorder (1 variants)
- Hypotonia (1 variants)
- Neurodevelopmental_abnormality (1 variants)
- Neurodevelopmental_disorder_with_microcephaly,_epilepsy,_and_brain_atrophy (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CHD1 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000001270.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 31 | 35 | ||||
missense | 263 | 20 | 293 | |||
nonsense | 13 | 14 | ||||
start loss | 0 | |||||
frameshift | 14 | 18 | ||||
splice donor/acceptor (+/-2bp) | 4 | |||||
Total | 3 | 6 | 296 | 52 | 7 |
Highest pathogenic variant AF is 0.00000657843
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CHD1 | protein_coding | protein_coding | ENST00000284049 | 35 | 71333 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 8.98e-10 | 125728 | 0 | 17 | 125745 | 0.0000676 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.21 | 507 | 853 | 0.594 | 0.0000430 | 11327 |
Missense in Polyphen | 48 | 255.07 | 0.18818 | 3227 | ||
Synonymous | 0.531 | 277 | 288 | 0.960 | 0.0000142 | 2976 |
Loss of Function | 8.28 | 9 | 96.9 | 0.0928 | 0.00000512 | 1289 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000470 | 0.0000462 |
European (Non-Finnish) | 0.000107 | 0.000105 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: ATP-dependent chromatin-remodeling factor which functions as substrate recognition component of the transcription regulatory histone acetylation (HAT) complex SAGA. Regulates polymerase II transcription. Also required for efficient transcription by RNA polymerase I, and more specifically the polymerase I transcription termination step. Regulates negatively DNA replication. Not only involved in transcription-related chromatin-remodeling, but also required to maintain a specific chromatin configuration across the genome. Is also associated with histone deacetylase (HDAC) activity (By similarity). Required for the bridging of SNF2, the FACT complex, the PAF complex as well as the U2 snRNP complex to H3K4me3. Functions to modulate the efficiency of pre-mRNA splicing in part through physical bridging of spliceosomal components to H3K4me3 (PubMed:18042460, PubMed:28866611). Required for maintaining open chromatin and pluripotency in embryonic stem cells (By similarity). {ECO:0000250|UniProtKB:P40201, ECO:0000269|PubMed:18042460, ECO:0000269|PubMed:28866611}.;
- Disease
- DISEASE: Pilarowski-Bjornsson syndrome (PILBOS) [MIM:617682]: An autosomal dominant disorder characterized by developmental delay, speech apraxia, intellectual disability, autism, and facial dysmorphic features. Some patients may have seizures. {ECO:0000269|PubMed:28866611}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- miR-targeted genes in epithelium - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase
(Consensus)
Recessive Scores
- pRec
- 0.173
Intolerance Scores
- loftool
- 0.0234
- rvis_EVS
- -0.81
- rvis_percentile_EVS
- 12.05
Haploinsufficiency Scores
- pHI
- 0.883
- hipred
- Y
- hipred_score
- 0.853
- ghis
- 0.571
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.592
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Chd1
- Phenotype
- vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; growth/size/body region phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); craniofacial phenotype; cellular phenotype;
Gene ontology
- Biological process
- chromatin remodeling;regulation of transcription by RNA polymerase II;covalent chromatin modification;DNA duplex unwinding;positive regulation by host of viral transcription
- Cellular component
- fibrillar center;nucleus;nucleoplasm;cytoplasm
- Molecular function
- DNA binding;ATP-dependent DNA helicase activity;protein binding;ATP binding;methylated histone binding